|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
December 19, 2005Nutra Pharma Reports Discovery of New Gene Involved in Multiple Sclerosis
Although the gene and some of its functions are already known, this is the first evidence of involvement with the disease state of MS. The research also provides evidence that RPI-78M modulates the expression of this gene in laboratory assays. RPI-78M is the lead drug candidate of Nutra Pharma's holding, ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating MS.MORE
|